Is Mobosetinib/Mobosetinib covered by medical insurance?

Mobocertinib/Mobocertinib is a targeted therapy for epidermal growth factor receptor (EGFR) mutations, specifically for patients with non-small cell lung cancer (NSCLC) with exon 20 insertion mutations. It is an oral tyrosine kinase inhibitor that inhibits the growth and spread of tumor cells by blocking the activity of the EGFR signaling pathway. Mechanistically, mobosetinib reduces the proliferation of tumor cells and induces apoptosis to a certain extent by selectively binding to and inhibiting the kinase activity of mutant EGFR, thereby improving the survival and quality of life of patients.

In clinical trials, mobosertinib showed good anti-tumor activity. According to relevant research data, mobosetinib can effectively alleviate the condition of patients who are resistant to other EGFR inhibitors, especially patients with exon 20 insertion mutations. This type of mutation often shows resistance in traditional EGFR inhibitor treatment. Therefore, the emergence of mobosetinib fills the gap in the treatment of these patients and provides them with new treatment options.

Regarding its marketing in China, mobosetinib was approved by the State Food and Drug Administration in 2023 and became the first targeted drug targeting EGFR exon 20 insertion mutations. Since its launch, the application of mobosetinib has gradually expanded, attracting the attention of medical staff and patients. The common 40mg 112-pellet specification sells for about 40,000 yuan per box. However, although its efficacy has been clinically verified, as of now, moboxetinib has not been included in the national medical insurance directory. Lack of medical insurance support means patients are responsible for higher drug costs themselves, which may affect their treatment options and financial burden.